Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9C0D0
UPID:
PHAR1_HUMAN
Alternative names:
-
Alternative UPACC:
Q9C0D0; A8K1V2; Q3MJ93; Q5JSJ2
Background:
Phosphatase and actin regulator 1, identified by the accession number Q9C0D0, is pivotal in cellular processes, including actin cytoskeleton dynamics, cell motility, and neuron migration. Its ability to bind actin monomers underscores its role in maintaining cellular structure and function.
Therapeutic significance:
Linked to Developmental and epileptic encephalopathy 70, a severe early-onset epilepsy, Phosphatase and actin regulator 1's genetic variants highlight its potential as a target for therapeutic intervention. Understanding its mechanisms offers a pathway to novel treatments for this debilitating condition.